Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM C HUANG

Allopathic & Osteopathic Physicians Urology

NPI
1235274101
CMS profile
192305
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$25,714.00

25 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $12,000.00 2
Consulting Fee $7,141.50 3
Travel and Lodging $4,177.89 5
Food and Beverage $1,454.61 13
Education $940.00 2

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
UROGEN PHARMA, INC. $17,767.92 15
Ferring Pharmaceuticals Inc. $3,761.23 3
HISTOSONICS, INC. $2,282.00 2
Janssen Scientific Affairs, LLC $1,690.02 3
Procept Biorobotics Corporation $178.43 1
INTUITIVE SURGICAL, INC. $34.40 1

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM C HUANG

NPI 1235274101 · CMS profile ID 192305

Allopathic & Osteopathic Physicians / Urology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235274101?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM C HUANG, NPI 1235274101, CMS profile ID 192305. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235274101?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). WILLIAM C HUANG, NPI 1235274101, CMS profile ID 192305. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235274101?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
WILLIAM C HUANG, NPI 1235274101, CMS profile ID 192305, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1235274101?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

25 matching records · $25,714.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 25 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–25 of 25.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ferring Pharmaceuticals Inc. $3,481.5012/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1242069709 CMS
UROGEN PHARMA, INC. $4,000.0012/04/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1244834248 CMS
UROGEN PHARMA, INC. $132.3012/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244834250 CMS
UROGEN PHARMA, INC. $58.3712/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244834252 CMS
Janssen Scientific Affairs, LLC $138.0211/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174184644 CMS
Ferring Pharmaceuticals Inc. $118.6411/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242069707 CMS
HISTOSONICS, INC. $32.0011/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233968127 CMS
UROGEN PHARMA, INC. $450.0010/29/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1244831859 CMS
UROGEN PHARMA, INC. $1,011.9310/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244831861 CMS
UROGEN PHARMA, INC. $58.4210/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244831863 CMS
HISTOSONICS, INC. $2,250.0010/06/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1221680154 CMS
Janssen Scientific Affairs, LLC $1,410.0009/23/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174183075 CMS
Janssen Scientific Affairs, LLC $142.0009/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174183768 CMS
UROGEN PHARMA, INC. $233.0008/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244831867 CMS
INTUITIVE SURGICAL, INC. $34.4007/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236627213 CMS
UROGEN PHARMA, INC. $8,000.0006/26/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1244828564 CMS
UROGEN PHARMA, INC. $303.9906/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244828566 CMS
UROGEN PHARMA, INC. $27.2606/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244849232 CMS
Ferring Pharmaceuticals Inc. $161.0906/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242069705 CMS
UROGEN PHARMA, INC. $1,174.1406/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244837622 CMS
UROGEN PHARMA, INC. $490.0006/11/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1244849110 CMS
UROGEN PHARMA, INC. $144.5206/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244839558 CMS
UROGEN PHARMA, INC. $1,655.8305/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244842722 CMS
UROGEN PHARMA, INC. $28.1605/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244831090 CMS
Procept Biorobotics Corporation $178.4304/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249757606 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,731.05 22
PY2020 $26.34 1
PY2021 $5,350.33 4
PY2022 $4,360.83 6
PY2023 $8,467.45 36
PY2024 $6,579.56 28
PY2025 $25,714.00 25

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $262,271.65 15
PY2024 Principal investigator $357,575.61 34
PY2023 Principal investigator $1,101,265.37 95
PY2022 Principal investigator $1,165,009.64 43
PY2021 Principal investigator $831,232.81 89
PY2020 Principal investigator $70,992.92 9
PY2019 Principal investigator $6,627.63 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

95 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 KARL STORZ Endoscopy-America $3,520.15 12/31/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Blue Light Flexible Cystoscopy with Cysview Study No dispute reported 06/30/2026 1052649811
Principal investigator 1 KARL STORZ Endoscopy-America $1,636.53 12/31/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Blue Light Flexible Cystoscopy with Cysview Study No dispute reported 06/30/2026 1052649813
Principal investigator 1 KARL STORZ Endoscopy-America $2,159.38 12/31/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Blue Light Flexible Cystoscopy with Cysview Study No dispute reported 06/30/2026 1052649815
Principal investigator 1 Merck Sharp & Dohme LLC $56,208.17 12/31/2023 Non-covered Recipient Entity
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na to BCG Treatment KEYNOTE-676 No dispute reported 06/30/2026 1042499453
Principal investigator 1 Merck Sharp & Dohme LLC $677,204.35 12/31/2023 Non-covered Recipient Entity
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na to BCG Treatment KEYNOTE-676 No dispute reported 06/30/2026 1042499463
Principal investigator 1 UROGEN PHARMA, INC. $74.68 12/31/2023 Non-covered Recipient Entity
NYU GROSSMAN SCHOOL OF MEDICINE
BL011 - A PHASE 3 SINGLE-ARM STUDY OF UGN -102 FOR TREATMENT OF LOW GRADE INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER (ENVISION) No dispute reported 06/30/2026 1038589355
Principal investigator 1 UROGEN PHARMA, INC. $779.23 12/31/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL011 - A PHASE 3 SINGLE-ARM STUDY OF UGN -102 FOR TREATMENT OF LOW GRADE INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER (ENVISION) No dispute reported 06/30/2026 1038592173
Principal investigator 1 Merck Sharp & Dohme LLC $331,950.98 12/01/2023 Non-covered Recipient Entity
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na to BCG Treatment KEYNOTE-676 No dispute reported 06/30/2026 1042501737
Principal investigator 1 UROGEN PHARMA, INC. $2,020.00 10/12/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038584567
Principal investigator 1 UROGEN PHARMA, INC. $101.95 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588123
Principal investigator 1 UROGEN PHARMA, INC. $101.95 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588137
Principal investigator 1 UROGEN PHARMA, INC. $101.95 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588151
Principal investigator 1 UROGEN PHARMA, INC. $101.95 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588167
Principal investigator 1 UROGEN PHARMA, INC. $101.95 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588181
Principal investigator 1 UROGEN PHARMA, INC. $55.25 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588197
Principal investigator 1 UROGEN PHARMA, INC. $55.25 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588317
Principal investigator 1 UROGEN PHARMA, INC. $55.25 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588345
Principal investigator 1 UROGEN PHARMA, INC. $55.25 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588375
Principal investigator 1 UROGEN PHARMA, INC. $55.25 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588391
Principal investigator 1 UROGEN PHARMA, INC. $75.56 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588405
Principal investigator 1 UROGEN PHARMA, INC. $108.06 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588501
Principal investigator 1 UROGEN PHARMA, INC. $108.06 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588517
Principal investigator 1 UROGEN PHARMA, INC. $108.06 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588845
Principal investigator 1 UROGEN PHARMA, INC. $108.06 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588859
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588871
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588885
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588895
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588915
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588925
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038588995
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589005
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589019
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589037
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589049
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589149
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589165
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589181
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589193
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589211
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589225
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589241
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589387
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589403
Principal investigator 1 UROGEN PHARMA, INC. $106.44 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589417
Principal investigator 1 UROGEN PHARMA, INC. $92.36 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589431
Principal investigator 1 UROGEN PHARMA, INC. $92.36 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589445
Principal investigator 1 UROGEN PHARMA, INC. $6.50 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589459
Principal investigator 1 UROGEN PHARMA, INC. $6.50 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589661
Principal investigator 1 UROGEN PHARMA, INC. $6.50 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589737
Principal investigator 1 UROGEN PHARMA, INC. $6.50 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589751
Principal investigator 1 UROGEN PHARMA, INC. $94.86 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589767
Principal investigator 1 UROGEN PHARMA, INC. $94.86 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589781
Principal investigator 1 UROGEN PHARMA, INC. $94.86 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589797
Principal investigator 1 UROGEN PHARMA, INC. $94.86 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589811
Principal investigator 1 UROGEN PHARMA, INC. $94.86 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589823
Principal investigator 1 UROGEN PHARMA, INC. $94.86 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589837
Principal investigator 1 UROGEN PHARMA, INC. $94.86 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589851
Principal investigator 1 UROGEN PHARMA, INC. $94.86 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589867
Principal investigator 1 UROGEN PHARMA, INC. $6.50 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589881
Principal investigator 1 UROGEN PHARMA, INC. $100.32 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589895
Principal investigator 1 UROGEN PHARMA, INC. $100.32 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589909
Principal investigator 1 UROGEN PHARMA, INC. $100.32 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589967
Principal investigator 1 UROGEN PHARMA, INC. $100.32 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038589983
Principal investigator 1 UROGEN PHARMA, INC. $100.32 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590371
Principal investigator 1 UROGEN PHARMA, INC. $94.86 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590385
Principal investigator 1 UROGEN PHARMA, INC. $94.86 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590401
Principal investigator 1 UROGEN PHARMA, INC. $94.86 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590415
Principal investigator 1 UROGEN PHARMA, INC. $94.86 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590429
Principal investigator 1 UROGEN PHARMA, INC. $6.50 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590473
Principal investigator 1 UROGEN PHARMA, INC. $6.50 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590487
Principal investigator 1 UROGEN PHARMA, INC. $199.45 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590529
Principal investigator 1 UROGEN PHARMA, INC. $199.45 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590613
Principal investigator 1 UROGEN PHARMA, INC. $199.45 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590627
Principal investigator 1 UROGEN PHARMA, INC. $199.45 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590643
Principal investigator 1 UROGEN PHARMA, INC. $199.45 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590655
Principal investigator 1 UROGEN PHARMA, INC. $199.45 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590669
Principal investigator 1 UROGEN PHARMA, INC. $199.45 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590763
Principal investigator 1 UROGEN PHARMA, INC. $6.50 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590805
Principal investigator 1 UROGEN PHARMA, INC. $6.50 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590819
Principal investigator 1 UROGEN PHARMA, INC. $6.50 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590851
Principal investigator 1 UROGEN PHARMA, INC. $6.50 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590865
Principal investigator 1 UROGEN PHARMA, INC. $6.50 08/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038590879
Principal investigator 1 UROGEN PHARMA, INC. $4,747.20 07/31/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL011 - A PHASE 3 SINGLE-ARM STUDY OF UGN -102 FOR TREATMENT OF LOW GRADE INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER (ENVISION) No dispute reported 06/30/2026 1038585824
Principal investigator 1 UROGEN PHARMA, INC. $454.98 07/31/2023 Non-covered Recipient Entity
NYU GROSSMAN SCHOOL OF MEDICINE
BL011 - A PHASE 3 SINGLE-ARM STUDY OF UGN -102 FOR TREATMENT OF LOW GRADE INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER (ENVISION) No dispute reported 06/30/2026 1038590013
Principal investigator 1 UROGEN PHARMA, INC. $1,802.44 05/17/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038584329
Principal investigator 1 UROGEN PHARMA, INC. $1,802.44 05/17/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038584341
Principal investigator 1 UROGEN PHARMA, INC. $1,906.18 05/17/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038584387
Principal investigator 1 UROGEN PHARMA, INC. $1,802.44 05/17/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038584401
Principal investigator 1 UROGEN PHARMA, INC. $185.25 04/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1038584763
Principal investigator 1 UROGEN PHARMA, INC. $741.00 04/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1038584774
Principal investigator 1 UROGEN PHARMA, INC. $741.00 04/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1038584860
Principal investigator 1 UROGEN PHARMA, INC. $741.00 04/19/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1038584877
Principal investigator 1 UROGEN PHARMA, INC. $1,802.44 03/11/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038584301
Principal investigator 1 UROGEN PHARMA, INC. $1,802.44 03/11/2023 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL006 - A PHASE 3 STUDY OF UGN-102 FOR LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (ATLAS) No dispute reported 06/30/2026 1038584313
Principal investigator 1 UROGEN PHARMA, INC. $461.70 01/09/2023 Non-covered Recipient Entity
NYU GROSSMAN SCHOOL OF MEDICINE
BL011 - A PHASE 3 SINGLE-ARM STUDY OF UGN -102 FOR TREATMENT OF LOW GRADE INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER (ENVISION) No dispute reported 06/30/2026 1038590027